DK1642576T3 - Anvendelse af pyrrolderivater til at bekæmpe angst - Google Patents

Anvendelse af pyrrolderivater til at bekæmpe angst

Info

Publication number
DK1642576T3
DK1642576T3 DK05028364T DK05028364T DK1642576T3 DK 1642576 T3 DK1642576 T3 DK 1642576T3 DK 05028364 T DK05028364 T DK 05028364T DK 05028364 T DK05028364 T DK 05028364T DK 1642576 T3 DK1642576 T3 DK 1642576T3
Authority
DK
Denmark
Prior art keywords
fight
anxiety
compound
pyrrole derivatives
isoindolinone
Prior art date
Application number
DK05028364T
Other languages
Danish (da)
English (en)
Inventor
Atul Chandra Pande
Cathyrn Montgomery Clary
Sean David Donevan
Perry Steven Eisman
Richard J Kavoussi
Lyou-Fu Ma
Beek Jeroen Bernard Van
Original Assignee
Indevus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indevus Pharmaceuticals Inc filed Critical Indevus Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1642576T3 publication Critical patent/DK1642576T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK05028364T 2001-04-30 2002-04-16 Anvendelse af pyrrolderivater til at bekæmpe angst DK1642576T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28754501P 2001-04-30 2001-04-30

Publications (1)

Publication Number Publication Date
DK1642576T3 true DK1642576T3 (da) 2009-04-14

Family

ID=23103396

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05028364T DK1642576T3 (da) 2001-04-30 2002-04-16 Anvendelse af pyrrolderivater til at bekæmpe angst

Country Status (21)

Country Link
US (2) US7026332B2 (de)
EP (2) EP1642576B1 (de)
JP (1) JP2002326934A (de)
KR (1) KR20020084413A (de)
CN (1) CN1384104A (de)
AT (2) ATE331513T1 (de)
AU (1) AU783516B2 (de)
CA (1) CA2383599C (de)
CY (1) CY1109129T1 (de)
DE (2) DE60231568D1 (de)
DK (1) DK1642576T3 (de)
ES (2) ES2323646T3 (de)
HK (1) HK1094307A1 (de)
HU (1) HU228826B1 (de)
IL (2) IL204665A (de)
MY (1) MY129575A (de)
NZ (1) NZ518615A (de)
PL (2) PL207738B1 (de)
PT (1) PT1642576E (de)
TW (1) TWI302455B (de)
ZA (1) ZA200203347B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0410419A (pt) * 2003-05-16 2006-05-30 Pfizer Prod Inc tratamento para a ansiedade com ziprasidona
CA2525866A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Treatment of psychotic and depressive disorders
KR100828218B1 (ko) * 2003-09-12 2008-05-07 화이자 인코포레이티드 알파-2-델타 리간드 및 세로토닌/노르아드레날린 재흡수 억제제를 포함하는 조합물
CN1878546A (zh) * 2003-09-12 2006-12-13 沃纳-兰伯特公司 治疗抑郁症和焦虑症的包括α－2δ配体和SSRI和/或SNRI的联用药物
WO2005105061A2 (en) * 2004-04-14 2005-11-10 Indevus Pharmaceuticals, Inc. Transdermal patch
WO2005107719A2 (en) * 2004-05-06 2005-11-17 Sandoz Ag Pharmaceutical composition comprising hydrophobic drug having improved solubility
EP2116618A1 (de) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnose und Behandlung des Kawasaki-Syndroms
JP2014506603A (ja) * 2011-02-25 2014-03-17 コンサート ファーマシューティカルズ インコーポレイテッド ２−アミノ−ナフチリジン誘導体
WO2020191047A1 (en) * 2019-03-18 2020-09-24 Neurocycle Therapeutics, Inc. Use of gabaa receptor modulators for treatment of pain

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2607503B1 (fr) 1986-12-02 1989-02-24 Rhone Poulenc Sante Nouveaux derives de l'isoindolinone, leur preparation et les compositions pharmaceutiques qui les contiennent
DE3814022A1 (de) 1988-04-26 1989-11-09 Davy Mckee Ag Verfahren zur herstellung linearer polyester, insbesondere fuer filme und folien
EP0521622B1 (de) 1991-07-03 1997-08-13 PHARMACIA & UPJOHN COMPANY Pyrazolopyrimiden- und Pyrimidinylbisphosphonsäureester als entzündungshemmende Mittel
FR2678932B1 (fr) 1991-07-12 1993-09-24 Rhone Poulenc Rorer Sa Procede de preparation des isomeres optiques d'un derive de l'amino-2 naphtyridine.
FR2678934B1 (fr) 1991-07-12 1995-01-13 Rhone Poulenc Rorer Sa Procede de preparation de l'isomere dextrogyre d'un derive de l'isoindolinone.
FR2681068B1 (fr) 1991-09-09 1993-11-19 Rhone Poulenc Rorer Sa Procede de preparation de l'isomere dextrogyre d'un derive de l'isoindolinone.
FR2684673B1 (fr) 1991-12-04 1994-01-21 Rhone Poulenc Rorer Sa Procede de preparation d'un derive de l'amino-2 naphtyridine racemique.
FR2687154B1 (fr) * 1992-02-07 1995-05-12 Rhone Poulenc Rorer Sa Nouveau derive de l'isoindolinone, sa preparation et les compositions pharmaceutiques qui le contiennent.
FR2695389B1 (fr) 1992-09-08 1994-11-04 Rhone Poulenc Rorer Sa Nouveau dérivé de l'isoindolinone, sa préparation et les compositions pharmaceutiques qui le contiennent.
US5498716A (en) 1994-01-12 1996-03-12 Rhone-Poulenc Rorer S.A. 2-amino naphthyridine derivative, its preparation and its use
GB2305859A (en) * 1996-03-29 1997-04-23 Lilly Co Eli Treatment of obsessive-compulsive disorder
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
WO2001008670A2 (en) * 1999-07-29 2001-02-08 Interneuron Pharmaceuticals, Inc. Methods and compositions for alleviating stuttering
DE19939980A1 (de) 1999-08-24 2001-03-01 Merck Patent Gmbh Inhibitoren des Integrins alphavbeta¶3¶
AU2756602A (en) * 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function

Also Published As

Publication number Publication date
ATE331513T1 (de) 2006-07-15
PL207725B1 (pl) 2011-01-31
EP1642576A3 (de) 2007-01-10
JP2002326934A (ja) 2002-11-15
PL207738B1 (pl) 2011-01-31
EP1254660A3 (de) 2003-03-26
CY1109129T1 (el) 2014-07-02
EP1642576B1 (de) 2009-03-11
PL390683A1 (pl) 2010-05-24
NZ518615A (en) 2004-03-26
AU2760902A (en) 2002-10-31
HUP0201394A3 (en) 2003-12-29
EP1254660A2 (de) 2002-11-06
ATE424820T1 (de) 2009-03-15
IL204665A (en) 2011-05-31
EP1642576A2 (de) 2006-04-05
IL149280A0 (en) 2002-11-10
US20030022915A1 (en) 2003-01-30
MY129575A (en) 2007-04-30
US7553847B2 (en) 2009-06-30
EP1254660B1 (de) 2006-06-28
CA2383599A1 (en) 2002-10-30
DE60231568D1 (de) 2009-04-23
US7026332B2 (en) 2006-04-11
HUP0201394A2 (hu) 2002-12-28
PL353681A1 (en) 2002-11-04
HU0201394D0 (de) 2002-06-29
TWI302455B (en) 2008-11-01
CN1384104A (zh) 2002-12-11
ES2267943T3 (es) 2007-03-16
PT1642576E (pt) 2009-05-21
DE60212757T2 (de) 2007-06-28
AU783516B2 (en) 2005-11-03
DE60212757D1 (de) 2006-08-10
US20060128746A1 (en) 2006-06-15
ES2323646T3 (es) 2009-07-22
KR20020084413A (ko) 2002-11-07
HU228826B1 (en) 2013-05-28
CA2383599C (en) 2006-10-31
HK1094307A1 (en) 2007-03-30
ZA200203347B (en) 2003-11-26

Similar Documents

Publication Publication Date Title
HK1094307A1 (en) Use of pyrrole derivatives to combat anxiety
FIC20210022I1 (fi) tukatinibi, valinnaisesti farmaseuttisesti hyväksyttävän suolan tai solvaatin muodossa
UY29919A1 (es) Derivados sustituidos de 3,4-dihidroisoquinolin-1-amino-trifluoroacetato, sus composiciones farmacéuticas y aplicaciones
DK1638941T3 (da) Indazol-, benzisoxazol- og benzisothiazolkinaseinhibitorer
EA200300788A1 (ru) Производные замещенных алкиламинов и их применение
ATE440603T1 (de) 8-hydroxychinolinderivate
HRP20090281T1 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
EA200301142A1 (ru) Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6
ATE554087T1 (de) Neue kinaseinhibitoren
EA200401160A1 (ru) Производные тиазола и оксазола, которые модулируют активность ppar
DK1578740T3 (da) 1,2,4-triaminobenzenderivater, der er egnede til behandling af lidelser i centralnervesystemet
ATE302775T1 (de) Carbolinderivate
CY1111858T1 (el) Ετεροκυκλικα παραγωγα ως διαμορφωτες υποδοχεα οπιοειδων
ATE277072T1 (de) Sapogenin derivate zur behandlung von kognitiven störungen
DE602005007765D1 (de) Neue indol- oder benzimidazol-derivate
DK1712225T3 (da) Substituered carbostyril-derivater som agonister af receptorundertype 5-HT 1A til behandling af bipolar lidelse
DK1448562T3 (da) Substituerede tetracycliske pyrroloquinolonderivater egnede som phosphodiesteraseinhibitorer
DK1373220T3 (da) Benzimidazoler, som er nyttige ved behandling af seksuel dysfunktion
BRPI0412636A (pt) imidazopirimidinas substituìdas para a prevenção e tratamento de cáncer
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
DK1301475T3 (da) Arylsulfonamider, som serotoninantagonist til behandling af obesitet
ATE407923T1 (de) Tyrosinderivate als phosphatase inhibitoren
DK1268482T3 (da) Pyranoindoler til behandling af glaukom
DE60142304D1 (de) Substituierte heterocyclische verbindungen und deren verwendung zur behandlung multipler medikamentenresistenz
DK1553938T3 (da) Anvendelse af epothilonderivater til behandling af hyperparathyroidisme